Endoscopic injection of fibrin glue into a bleeding peptic ulcer is an effective and safe treatment modality. The present report describes a patient who developed rectal bleeding from an arteriovenous malformation after endoscopic injection of fibrin glue containing human thrombin into a gastric ulcer. Additional laboratory investigations revealed the presence of an inhibitor against coagulation factor V, which resulted in severe coagulopathy, triggering the bleeding. Acquired factor V inhibitors have frequently been reported with the use of bovine thrombin, but to our knowledge, they have never been documented in patients exposed to human thrombin. Endoscopists should be aware of this rare, but potentially serious, complication.
References
-
1
Van de Mierop F, Fleischer D.
Endoscopic hemostasis in nonvariceal bleeding: an overview.
Endoscopy.
1996;
28
54-65
-
2
Rutgeerts P, Rauws E, Wara P. et al .
Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer.
Lancet.
1997;
350
692-696
-
3
Berg P L, Barina W, Born P.
Endoscopic injection of fibrin glue versus polidocanol in peptic ulcer hemorrhage: a pilot study.
Endoscopy.
1994;
26
528-530
-
4
Kubba A K, Murphy W, Palmer K R.
Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin.
Gastroenterology.
1996;
111
623-628
-
5
Chouhan V D, De La Cadena R A, Nagaswami C. et al .
Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Thromb Haemost.
1997;
77
343-349
-
6
Knobl P, Lechner K.
Acquired factor V inhibitors.
Baillière’s Clin Haematol.
1998;
11
305-318
-
7
Ortel T L, Charles L A, Keller F G. et al .
Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.
Am J Hematol.
1994;
45
128-135
-
8
Berruyer M, Amiral J, Ffrench P. et al .
Immunization by bovine thrombin used with fibrin glue during cardiovascular operations: development of thrombin and factor V inhibitors.
J Thorac Cardiovasc Surg.
1993;
105
892-897
-
9
Spero J A.
Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients: report of three cases.
J Neurosurg.
1993;
78
817-820
-
10
Feinstein D I, Rapaport S I, Chong M M.
Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin.
Ann Intern Med.
1973;
78
385-388
-
11
Alving B M, Weinstein M J, Finlayson J S. et al .
Fibrin sealant: summary of a conference on characteristics and clinical uses.
Transfusion.
1995;
35
783-790
-
12
Banninger H, Hardegger T, Tobler A. et al .
Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V.
Br J Haematol.
1993;
85
528-532
-
13
Ortel T L, Moore K D, Quinn-Allen M A. et al .
Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.
Blood.
1998;
91
4188-4196
-
14
Chediak J, Ashenhurst J B, Garlick I, Desser R K.
Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions.
Blood.
1980;
56
835-841
-
15
Chiu H C, Rao A K, Beckett C, Colman R W.
Immune complexes containing factor V in a patient with an acquired neutralizing antibody.
Blood.
1985;
65
810-818
-
16
Tarantino M D, Ross M P, Daniels T M, Nichols W L.
Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin.
J Pediatr Hematol Oncol.
1997;
19
226-231
-
17
Fu Y X, Kaufman R, Rudolph A E, Collum S E, Blinder M A.
Multimodality therapy of an acquired factor V inhibitor.
Am J Hematol.
1996;
51
315-318
-
18
Tribl B, Knobl P, Derfler K. et al .
Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.
Ann Hematol.
1995;
71
199-203
H. Reynaert, M. D.
Dept. of Gastroenterology
University Hospital · Free University of Brussels (AZ VUB) · Laarbeeklaan 101 · 1090 Brussels · Belgium
Fax: + 32-2-477 68 10
Email: Hendrik.Reynaert@az.vub.ac.be
